MedTrace Logo

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

NCT00617864 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-02-22

No results posted yet for this study

Summary

This research study was designed to look at the effect of human albumin transfusion on circulating levels of Vascular Endothelial Derived Growth Factor (VEGF), a protein that is believed to be responsible for the syndrome of ovarian hyperstimulation. Patients have been asked to participate because they are identified as at risk for the Ovarian Hyperstimulation Syndrome (OHSS), a potentially serious complication of in vitro fertilization. It has been established that the onset of OHSS may be preventable by the infusion of albumin at the time of egg retrieval; however, we do not know by what mechanism albumin works. As we know the pathogenesis of OHSS is related to VEGF released from the ovaries, we believe human albumin may serve to "bind up" this VEGF and prevent it from causing its harmful effects. The purpose of this study is to evaluate the effect of albumin infusion on blood and urine VEGF levels in these patients.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Human Albumin Infusion

Group will receive single infusion of albumin at the time of oocyte retrieval.

DRUG

Saline Infusion

Group will receive single infusion of saline at the time of oocyte retrieval.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Pasquale Patrizio, MD, MBE, HCLD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617864 on ClinicalTrials.gov